Having established that activation of CD28 enhances the activity of AMG 330 in leukemic cell lines, we aimed to assess whether activation of CD28 also impacted the efficacy of BiTE antibody constructs against primary patient leukemia cells. This evidence concerns the gene CD28 and leukemia.